You are here
Interview with Ludwig Kappos: Effect of daclizumab HYP vs. intramuscular interferon beta-1a on no evidence of disease activity in patients with relapsing-remitting MS: analysis of the DECIDE Study
Professor Kappos and his colleagues conducted a randomized, double-blind, active-controlled, international phase 3 study (the DECIDE study] involving 1841 patients with relapsing–remitting multiple sclerosis, in order to compare daclizumab HYP [high yield process], administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 μg once weekly, for up to 144 weeks. Daclizumab is a therapeutic humanized monoclonal antibody to the interleukin-2 receptor.
After a specific time period Kappos et al. counted the patients with no new clinical activity, no disability progression and no new or newly enlarged hyperintense lesions on T2-weighted magnetic resonance imaging. This gave the overall value for NEDA [no evidence of disease activity].
The rate of NEDA with daclizumab HYP was twice that with interferon beta-1a. This was also true of subgroups, particularly those patients who had already had experience with the comparator interferon beta-1a. Thus daclizumab HYP was superior to interferon beta-1a. This is also consistent with the results for the individual outcomes.
Dr. Kappos is Professor of Neurology at Basel University Hospital, Switzerland.
This interview has been recorded at ECTRIMS 2015, October 2015, Barcelona, Spain.